Cookies is a company that operates in the cannabis industry. The company offers a range of cannabis products, including CBD, Delta 8, HHC, and THCa, which are intended for use by individuals over the age of 21. It is based in San Francisco, California.
Latest Cookies News
Sep 28, 2022
The licensing agreement will see Cookies genetics land in European cannabis markets for the first time. September 28, 2022 Courtesy of Akanda Corp. With an exclusive licensing agreement now on the books, Cookies genetics will be grown, harvested and sold as medical cannabis products by Akanda Corp. , a cultivation and manufacturing firm based in Portugal. Summing up the news, Akanda CEO Tej Virk said, “Akanda has secured one of the most prized cannabis assets in Europe.” Virk’s company boasts a 20,000-sq.-ft. indoor cultivation site (located in Sintra, Portugal, with a capacity of 2,000 kg of harvested cannabis per year) and a mixed outdoor-greenhouse site (located in Aljustrel). It was the Sintra facility that really grabbed the attention of Cookies executives. Across the fledgling medical cannabis markets of Europe, indoor cultivation is a rare breed. Virk ballparked his company’s flower supply above the 20% THC threshold. “We’re trying to lead the charge here in quality and innovation,” he said. With the Cookies deal, Akanda will have a high-profile opportunity to prove itself to Europe. At the heart of this deal is a connection to the roots of the global cannabis industry—in California. Virk said that demand is strong for California cultivars and for Cookies’ extensive genetics library. This licensing agreement bridges a considerable gap between European medical cannabis patients and the California market. “The cannabis industry is still a people business,” Virk said, noting Akanda had acquired its cultivation facilities from Holigen earlier this year. The Holigen team had a preexisting relationship with Cookies that helped pave the way to this month’s exclusive deal. While Akanda has not yet disclosed which cultivars will be grown and sold, Virk said that the Cookies team has committed to collaborative approach to cultivation in Sintra. It will take some time to develop strong mother plants, and Virk pointed to sometime in 2023 for sales to medical patients. To give the deal even more sizzle, Akanda Corp. had just recently inked a distribution agreement with Cansativa. The multi-year agreement will see Cansativa distributing Akanda-grown cannabis to Germany’s medical market. Virk said that this is a huge turn for the company. The European cannabis markets are led by Germany, and now Akanda is positioned to hold at least a 10% market share of medical cannabis products in the country, according to a recent press release announcing the first shipment from Sintra. “[Cansativa] optioned into the entire capacity for our indoor premium site,” Virk said. What makes the prospect even more noteworthy is that Germany could possibly legalize adult-use cannabis sales next year or in 2024; the German federal parliament held multiple hearings on the topic this summer. “We’ve publicly declared that we want to participate in the adult-use market,” Virk said. “As soon as we see a clear framework we want to be involved. While Oct. 1 is the tentative date for adult-use cannabis retailers to launch commercial sales in Vermont, nothing is stopping three licensees from opening their doors earlier if they so choose. Once businesses have their licenses fully issued—meaning they received local permits where applicable, met any outstanding contingencies on their license and paid associated fees—they may begin operations, Nellie Marvel, outreach and education manager for the Vermont Cannabis Control Board (CCB), told Cannabis Business Times. There are three businesses that have been approved for retail sales across the state at this point, she said. At its Sept. 14 board meeting, the CCB issued those adult-use retail licenses to Mountain Girl Cannabis in Rutland, FLORA Cannabis in Middlebury, and CeresMED—formerly Champlain Valley Dispensary—an existing medical cannabis operator in South Burlington. “There’s nothing specifically saying that businesses must wait until Oct. 1 to begin sales, if they’re licensed,” Marvel said. “They may opt to do so, as that’s the date everyone is familiar with, but they do not necessarily have to. Others may opt to wait until the supply chain becomes more established—this is a decision every business owner will have to make for themselves.” At least one retail licensee plans to launch adult-use sales on Oct. 1, according to VT Digger : FLORA Cannabis. The four-plus-year buildup to this point includes Gov. Phil Scott signing adult-use legislation in January 2018. The legislation took effect July 1 of that year—allowing those 21 and older to possess limited amounts of cannabis and grow it in their homes—marking the first time any state legislature legalized cannabis for adults through the legislative process rather than by a people’s vote on a ballot measure. The Vermont Legislature then passed Act 164 in 2020, which established a taxation and regulation system for cannabis. That act also set a timeline for the rollout of the state’s adult-use market with specific dates for various industry licensures. That’s where the Oct. 1, 2022, date to license retailers was established. While CCB members missed a May 1 deadline to begin issuing adult-use licenses for small cultivators and testing laboratories amidst “staffing shortages” this year, regulators issued the state’s first cannabis cultivation license to an indoor grower in Rutland County on May 16 and three more the following week. With a roughly six-month timeline for growing, drying and curing, supply for an expanded market may be short of demand from the onset of an adult-use retail launch in Vermont. Nevertheless, three businesses have the green light to open dispensaries, and there’s a possibility of more retail licenses being issued by the CCB at its Sept. 28 meeting. “It’s also important to underscore that these first licensed retailers don’t represent the end of the road in the journey towards a more sensible regulated cannabis market in Vermont,” Marvel said. “Delays in licensing at the beginning of the process, especially for our outdoor cultivators, means that not everyone was able to participate in the market fully this year. This also means we’re likely to see early supply shortages, which has happened in the initial rollout of each adult-use state as the supply chain continues to develop.” SAN JOSE, California, Sept. 27, 2022 - PRESS RELEASE - TPCO Holding Corp . (The Parent Company), a consumer-focused California cannabis company, announced that it has acquired the remaining 15% equity of its Calma Weho LLC (Calma) dispensary following receipt of all necessary regulatory approvals. Located in the Los Angeles metropolitan region, the 3,250-square-foot dispensary is one of eleven stores in the West Hollywood area that is licensed for storefront retail and is surrounded by cultural destinations and tourist attractions in every direction. Since the first closing, the company has rolled out its full brand offering and recently debuted its Monogram "store within a store" concept, providing consumers a curated experience of the Monogram brand and line of products. "The energy and excitement at Calma are fantastic, and it boasts the best flower assortment in West Hollywood," said Troy Datcher, The Parent Company CEO and chairman. "It's both a beautiful dispensary and an incredible gathering space that we have used to host events and collaborations, including our recent FaZe Rain RCVRY product launch, which saw phenomenal community response and surpassed our expectations. With an intentional menu selection that showcases a variety of consumption methods, Calma caters to both those about to embark on their cannabis journey as well as experienced connoisseurs, and we are thrilled to have now completed the acquisition." In connection with the final closing of the acquisition, The Parent Company issued an aggregate $1.5 million common shares of the company to equity holders of Calma. PHOENIX, Arizona, Sept. 27, 2022 - 4Front Ventures Corp. , a vertically integrated, multi-state cannabis operator and retailer, announced the launch of its premier California cannabis brand, Island Cannabis Co ., in Massachusetts. Following the company's acquisition of Island, a California-based producer of prerolls, flower and concentrate products, in April, the company began cultivating 11 new Island flower strains at its state-of-art flower facilities located in Holliston, Georgetown and Worcester, Mass. The 11 new Island strains include Project 4516; The Cypher; Banana Puddintain; Garlic Z; Star 91; Mimosa; London Pound Mints; TK-43; Wonka Bars; Cookies & Cream; and Grapes n' Cream. Each strain has been hand-selected for its unique genetic lineage, terpene profile, potency, and nose. Island's new strains are initially available for purchase exclusively at 4Front's Mission Dispensaries in Georgetown, Worcester and Brookline, and are expected to roll out to partner dispensaries across the Bay State in the coming weeks. "After our acquisition of Island earlier this year, we quickly set out to strategically bring the very best the brand had to offer to our customers, and I couldn't be more pleased with how quickly and efficiently our team was able to deliver these popular California fan favorites to Massachusetts consumers," 4Front CEO Leo Gontmakher said. "With the launch of Island in the Bay State, we're confident that even the pickiest of cannabis connoisseurs will fall in love with these strains and that, as a whole, the brand will create a loyal following, just as it has in the Golden State. We also look forward to bringing additional high-quality flower products from Island to Massachusetts in the very near future, including larger format flower offerings and Island's best-selling prerolls and infused prerolls in singles and multipacks." 4Front President of Massachusetts Operations and Island Co-Founder Brandon Mills added, "Taking proven products and brands like Island and strategically launching them in key markets is one of the things we do best. With the launch of Island in Massachusetts, we took the best operational practices our team learned from years of cultivating and manufacturing in California, and married them with in-market expertise at our facilities in Holliston, Georgetown and Worcester. Bringing together best-in-class genetics, cultivation practices, and production technology, we're delivering a premium cannabis value proposition, coast-to-coast."
Cookies Frequently Asked Questions (FAQ)
Where is Cookies's headquarters?
Cookies's headquarters is located at San Francisco.
What is Cookies's latest funding round?
Cookies's latest funding round is Seed VC.
Who are the investors of Cookies?
Investors of Cookies include 12/12 Ventures.